『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=377435)

EID=377435EID:377435, Map:0, LastModified:2021年7月28日(水) 12:53:30, Operator:[西岡 安彦], Avail:TRUE, Censor:0, Owner:[西岡 安彦], Read:継承, Write:継承, Delete:継承.
○種別 (必須): □学術論文 (審査論文) [継承]
○言語 (必須): □英語 [継承]
○招待 (推奨):
○審査 (推奨):
○カテゴリ (推奨):
○共著種別 (推奨):
○学究種別 (推奨):
○組織 (推奨):
○著者 (必須): 1. (英) Okada Naoto (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
2. (英) Matsuoka Rie (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
3. (英) Sakurada Takumi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
4. (英) Goda Mitsuhiro (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
5. (英) Chuma Masayuki (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
6. (英) Yagi Kenta (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
7. (英) Zamami Yoshito (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
8.西岡 安彦 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
9.石澤 啓介 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.臨床薬理学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
○題名 (必須): □(英) Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.  (日)    [継承]
○副題 (任意):
○要約 (任意): □(英)   (日) Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lung cancer. Therefore, early ICI-ILD detection and intervention are important for patient safety. However, a risk assessment method for ICI-ILD has not been established and the prediction of ICI-ILD occurrence is difficult. The aim of our study was to identify the risk factors associated with ICI-ILD. To this end, we retrospectively analysed 102 patients with lung cancer who first received ICI and completed the treatment between April 2016 and December 2019 at Tokushima University Hospital. Nineteen patients had all grades of ICI-ILD and 10 had grade ≥ 3 ICI-ILD. The 30-day mortality rate of patients with grade ≥ 3 ICI-ILD was the highest among all patients (P < 0.01). The multivariate logistic analysis indicated that the performance status ≥ 2 alone and both performance status ≥ 2 and ≥ 50 pack-year were independent risk factors of ICI-ILD of grade ≥ 3 and all grades, respectively. Overall, our study provides insights to predict ICI-ILD occurrence.   [継承]
○キーワード (推奨): 1. (英) Adult (日) (読) [継承]
2. (英) Aged (日) (読) [継承]
3. (英) Aged, 80 and over (日) (読) [継承]
4. (英) Antibodies, Monoclonal (日) (読) [継承]
5. (英) Antibodies, Monoclonal, Humanized (日) (読) [継承]
6. (英) B7-H1 Antigen (日) (読) [継承]
7. (英) CTLA-4 Antigen (日) (読) [継承]
8. (英) Carcinoma, Non-Small-Cell Lung (日) (読) [継承]
9. (英) Early Diagnosis (日) (読) [継承]
10. (英) Female (日) (読) [継承]
11. (英) Humans (日) (読) [継承]
12. (英) Immune Checkpoint Inhibitors (日) (読) [継承]
13. (英) Lung Diseases, Interstitial (日) (読) [継承]
14. (英) Lung Neoplasms (日) (読) [継承]
15. (英) Male (日) (読) [継承]
16. (英) Middle Aged (日) (読) [継承]
17. (英) Nivolumab (日) (読) [継承]
18. (英) Programmed Cell Death 1 Receptor (日) (読) [継承]
19. (英) Retrospective Studies (日) (読) [継承]
20. (英) Risk Assessment (日) (読) [継承]
21. (英) Risk Factors (日) (読) [継承]
○発行所 (推奨):
○誌名 (必須): □Scientific Reports ([Nature Publishing Group])
(eISSN: 2045-2322)

○ISSN (任意): □2045-2322
ISSN: 2045-2322 (eISSN: 2045-2322)
Title: Scientific reports
Title(ISO): Sci Rep
Publisher: Nature Portfolio
 (NLM Catalog)   (Scopus)   (CrossRef)  (Scopus information is found. [need login])
[継承]
[継承]
○巻 (必須): □10 [継承]
○号 (必須): □1 [継承]
○頁 (必須): □ [継承]
○都市 (任意):
○年月日 (必須): □西暦 2020年 8月 13日 (令和 2年 8月 13日) [継承]
○URL (任意):
○DOI (任意): □10.1038/s41598-020-70743-2    (→Scopusで検索) [継承]
○PMID (任意): □32792640    (→Scopusで検索) [継承]
○CRID (任意):
○WOS (任意):
○Scopus (任意):
○評価値 (任意):
○被引用数 (任意):
○指導教員 (推奨):
○備考 (任意): 1.(英) PublicationType: Journal Article  (日)    [継承]
2.(英) PublicationType: Research Support, Non-U.S. Gov't  (日)    [継承]

標準的な表示

和文冊子 ● Naoto Okada, Rie Matsuoka, Takumi Sakurada, Mitsuhiro Goda, Masayuki Chuma, Kenta Yagi, Yoshito Zamami, Yasuhiko Nishioka and Keisuke Ishizawa : Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study., Scientific Reports, Vol.10, No.1, 2020.
欧文冊子 ● Naoto Okada, Rie Matsuoka, Takumi Sakurada, Mitsuhiro Goda, Masayuki Chuma, Kenta Yagi, Yoshito Zamami, Yasuhiko Nishioka and Keisuke Ishizawa : Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study., Scientific Reports, Vol.10, No.1, 2020.

関連情報

Number of session users = 1, LA = 0.67, Max(EID) = 415393, Max(EOID) = 1122840.